Expression of TNFα by CD3+ and F4/80+ cells following irradiation preconditioning and allogeneic spleen cell transplantation

Bone Marrow Transplantation

Volumn 33, Issue 4, 2004, Pages 359-365

  Brown, S ^a,b   Konopa, J ^b   Zhou, D ^c   Thompson, J ^a,b  

^a LEXINGTON VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

GVHD; Macrophage; T cell; TNF

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; DIFFERENTIATION ANTIGEN; MONOCYTE MACROPHAGE DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN;

ACUTE DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGENIC SPLEEN CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DONOR; FREQUENCY ANALYSIS; GRAFT VERSUS HOST REACTION; HOST CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; WHOLE BODY RADIATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL TRANSPLANTATION; CYTOLOGY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; METHODOLOGY; SPLEEN;

ANIMALS; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION; CELL TRANSPLANTATION; GRAFT VS HOST DISEASE; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPLEEN; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA; WHOLE-BODY IRRADIATION;

EID: 1542359633     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704362     Document Type: Article

References (31)

1. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
2. Nagler A, Bishara A, Brautbar C, Barak V. Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation. Cytokines Cell Mol Ther 1998; 4: 161-167.
3. Piquet PF, Grau GE, Allet B, Vassalli PJ. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1280-1289.
4. Racadot E, Milpied N, Bordigoni P et al. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicenter pilot study including 15 patients. Bone Marrow Transplant 1995; 15: 669-677.
5. Herve P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-3368.
6. Hattori K, Hirano M, Yamakawa N et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor antibodies on acute graft-versus-host disease pathologies. Blood 1998; 91: 4051-4055.
7. Brown GR, Lingberg G, Meddings J et al. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology 1999; 116: 593-601.
8. Ferrara JLM. Cytokine inhibitors and graft-versus-host disease. Ann N Y Acad Sciences 1995; 770: 227-236.
9. Tsukada N, Kobata T, Aizawa Y et al. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999; 93: 2738-2747.
10. Speis DE, Bachmann MF, Frick TW et al. TNF receptor p55 controls early acute graft-versus-host disease. J Immunol 1997; 158: 5185-5190.
11. Sherman ML, Datta R, Hallahan DE et al. Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. J Clin Invest 1991; 87: 1794-1797.
12. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
13. Schmaltz C, Alpdogan O, Muriglan SJ et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003; 101: 2440-2445.
14. Zhou D, Brown SA, Yu T et al. Ionizing irradiation induces tissue-specific activation of nuclear factor-κB in vivo. Radiat Res 1999; 151: 703-709.
15. Zhou D, Yu T, Chen G et al. Effects of NF-κB1 (p50) targeted gene disruption on ionizing radiation-induced NF-κB activation and TNFα, IL-1a, IL-1B and IL-6 mRNA expression in vivo. Int J Radiat Biol 2001; 77: 763-772.
16. Baeuerle PA, Hinkel T. Function and activation NF-κB in the immune system. Annu Rev Immunol 1996; 14: 649-681.
17. Korngold R, Sprent JJ. Lethal graft-versus-host-disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978; 148: 1687-1698.
18. Ho VT, Soiffer RJ. The history and future of T cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192-3204.
19. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
20. Hill GR, Crawford JM, Cooke KR et al. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
21. Hill GR, Cooke KR, Brinson YS et al. Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 1999; 67: 1478-1480.
22. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991; 77: 2515-2523.
23. Xun CQ, Tsuchida M, Thompson JS. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation 1997; 64: 297-302.
24. Iwamoto KS, McBride WH. Production of 13-hydroxyoctadecadienoic acid and tumor necrosis factor-alpha by murine peritoneal macrophages in response to irradiation. Radiat Res 1994; 139: 103-108.
25. Lucas M, Stuart LM, Savill J, Lacy- Hulbert A. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J Immunol 2003; 171: 2610-2615.
26. Weill D, Gay F, Tovy MG, Chouaib S. Induction of tumor necrosis factor alpha expression in human T lymphocytes following ionizing gamma irradiation. J Interferon Cytokine Res 1996; 16: 395-402.
27. Butturini A, Seeger RC, Gale RP. Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood 1986; 68: 954-956.
28. Slordal L, Muench MO, Warren DJ, Moore MA. Radioprotection by murine and human tumor-necrosis factor: dose dependent effects on hematopoiesis in the mouse. Eur J Haematol 1989; 43: 428-434.
29. Dalmau SR, Freitas CS, Savino W. Radio- and chemoprotection of bone marrow cells by opposite cell cycle-acting cytokines. Leuk Res 1997; 21: 93-99.
30. Song HK, Noorchashm H, Lieu YK et al. Cutting edge: alloimmune responses against major and minor histocompatibility antigens: distinct division kinetics and requirement for CD28 costimulation. J Immunol 1999; 162: 2467-2471.
31. Price KS, Nestel FP, Lapp WS. Progressive accumulation of bacterial lipopolysaccharide in vivo during murine acute graft-versus-host disease. Scand J Immunol 1997; 45: 294-300.